Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-Cell NHL Subtypes.
Lynn I LevinChristina M RamirezEileen Lingchen LiaoHongyu GuoBong K KimAizen J MarrogiLarry I MagpantayElizabeth Crabb BreenOtoniel Martinez-MazaPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)
The increasing trajectories of the B-cell activation molecules, sCD30, CXCL13, and to a lesser extent IL-10, may indicate early disease-induced effects or reflect the chronic stimulation of B cells that promotes the development of FL and DLBCL subtypes.